Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
January 10, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved...
September 20, 2023 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: More than 30 million people in the United States suffer with a rare disease; most of them are...
Roche to provide HIV diagnostic solutions to Global Fund PR Newswire PLEASANTON, California, June 18, 2015 - Framework agreement with Global Fund strengthens access to HIV diagnostics ...
Clinical value of Roche's CINtec® PLUS Cytology test confirmed for women with abnormal cervical cytology screening results PR Newswire TUCSON, Ariz., June 16, 2015 TUCSON, Ariz., June 16, 2015...
Ventana receives FDA approval for the first fully automated IHC companion diagnostic to identify lung cancer patients eligible for XALKORI® (crizotinib) PR Newswire TUCSON, Arizona, June 15, 2015...
Ariosa receives CE mark for its FORTE Software to support Harmony™ Prenatal Test PR Newswire SAN JOSE, Calif., June 11, 2015 SAN JOSE, Calif., June 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG;...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.08 | -5.58989518947 | 37.21 | 37.27 | 35.03 | 1031375 | 35.98069641 | DR |
| 4 | -4.76 | -11.9328152419 | 39.89 | 40.67 | 35.03 | 1159660 | 38.59951372 | DR |
| 12 | -6.65 | -15.9167065582 | 41.78 | 42.43 | 35.03 | 1358162 | 39.0973737 | DR |
| 26 | 2.13 | 6.45454545455 | 33 | 42.43 | 31.19 | 1733717 | 37.13131885 | DR |
| 52 | 1.76 | 5.27419838178 | 33.37 | 42.43 | 29.2 | 2075145 | 34.52768357 | DR |
| 156 | -14.28 | -28.9010321797 | 49.41 | 53.86 | 27.95 | 1851740 | 38.249473 | DR |
| 260 | -3 | -7.86782061369 | 38.13 | 53.86 | 27.95 | 1739882 | 39.98221416 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
